Premium
OP01.06: Targeted cfDNA analysis using DANSR assays for determination of fetal RHD status
Author(s) -
Saini S.,
Foley R.,
Kingsley C.,
Wang E.,
Bogard P.,
Schmid M.
Publication year - 2018
Publication title -
ultrasound in obstetrics and gynecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.202
H-Index - 141
eISSN - 1469-0705
pISSN - 0960-7692
DOI - 10.1002/uog.19396
Subject(s) - fetus , medicine , pregnancy , cell free fetal dna , prenatal diagnosis , obstetrics , andrology , genetics , biology
Disclosure: All authors are employees of Ariosa Diagnostics Inc., and Roche Sequencing Solutions Inc. Methods 12 simulated pregnancy plasma samples with known RHD genotype were prepared by titrating non-pregnant, RHD-positive cfDNA (fetal source) into non-pregnant, female RHD-negative cfDNA (maternal source) to simulate fetal fractions of 5%, 10% and 15%. A 0% sample served as a negative control. Digital Analysis of Selected Regions (DANSR) assays targeting exons 2, 3, 4, 5 and 7 of the RHD gene were added to existing DANSR assays and the generated DANSR products were hybridized onto a custom DNA microarray for analysis of fetal fraction and determination of fetal RHD status using the fetal fraction optimized FORTE algorithm.